Dr. Reddy's reports Q4 FY26 results with 19.5% EBITDA margin and double-digit base business growth.
Company achieves first global approval for generic semaglutide injection in Canada and launches it in India as Obeda®.
Secures USFDA review for abatacept biosimilar BLA and completes 95% integration of acquired NRT business by value.
Receives Gold Medal from EcoVadis with a score of 80 and 'Leadership' in Indian Corporate Governance for third year.